Cervimark LLC have developed a way to identify biomarkers that are a factor in preterm births. Cervimark's next step: a clinical trial that will enroll 200 to 300 pregnant mothers who could be at risk for preterm delivery. That test phase should take another six months to a year. If the results continue to be positive, Cervimark expects to apply for an NIH grant of $1 million for a larger study before taking any test to market. The test is not a treatment. At-risk patients could use the results to take steps to minimize the danger of a preterm birth, such as relocating from a rural area closer to medical facilities that can handle the condition or modifying their lifestyle. Based on the results, doctors also could recommend additional medical treatments.